Steven Bishay, W Hudson Robb, Trent M Schwartz, David S Smith, Lok Hin Lee, Cynthia J Lynn, Tammy L Clark, Angela L Jefferson, Jeremy L Warner, Eben L Rosenthal, Barbara A Murphy, Timothy J Hohman, Mary Ellen I Koran
BACKGROUND AND PURPOSE: Adverse neurological effects after cancer therapy are common, but biomarkers to diagnose, monitor, or risk stratify patients are still not validated or used clinically. An accessible imaging method, such as fluorodeoxyglucose positron emission tomography (FDG PET) of the brain, could meet this gap and serve as a biomarker for functional brain changes. We utilized FDG PET to evaluate which brain regions are most susceptible to altered glucose metabolism after chemoradiation in patients with head and neck cancer (HNCa)...
December 26, 2023: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging